Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Biosecurity topic
No spam. Unsubscribe anytime.
Lawmakers consider bills to bar insurance coverage tied to organ procurement or genomics from Chinese entities after national security testimony
Summary
Two bills — one prohibiting coverage for transplants performed in China or sourced from Chinese procurement, and another limiting use of genomic sequencers from firms domiciled in foreign adversary countries — drew testimony on documented allegations of forced organ harvesting and on security risks from foreign access to genomic data. Committee
Two related bills drew committee attention to national‑security risks tied to organ procurement and genetic‑sequencing technology.
Organ‑procurement coverage restriction (HB 21‑09): Rep. Biasucci introduced HB 21‑09 to allow insurers to limit coverage for transplants performed in the People’s Republic of China or the Hong Kong Special Administrative Region or for organs procured by sale or donation originating there. Supporters argued the PRC has a history of coerced organ procurement; witness testimony described investigations and reports alleging organ sales and a fast‑track system for international organ recipients. The Arizona ACLU and human‑rights lawyers urged removal of stigmatizing policies in other bills but supported this bill as a measure to avoid subsidizing human‑rights abuses. The committee gave HB 21‑09 a due‑pass recommendation (7 ayes, 5 nays).
Genomic sequencing and foreign adversary restrictions (HB 26‑93): HB 26‑93 would allow insurers to limit coverage for genetic sequencing performed on devices or software produced by companies domiciled in or substantially controlled by a foreign adversary; it would also prohibit certain use and procurement of sequencers by health institutions and research facilities. Testimony cited documented concerns about Chinese firms’ relationships with the People’s Liberation Army, congressional inquiries and a former PLA official’s statements about genetically targeted weapons. Proponents argued the PRC’s national intelligence and industrial policy make genomic data a strategic risk, and they cited recent federal cybersecurity advisories about medical devices exfiltrating patient data to Chinese servers. The committee returned HB 26‑93 with a due‑pass recommendation by roll call (9 ayes, 3 nays).
Why it matters: Witnesses described how rapid transplants scheduled abroad or genetic databases accessible to adversary states could present biosecurity and human‑rights problems, and several members echoed concerns about protecting patient privacy and preventing state‑sponsored misuse of health data. Opponents urged careful drafting to avoid disrupting clinical research and legitimate cross‑border medical collaboration.
Committee action: Both bills received committee recommendations to proceed; members asked for continued coordination with federal agencies and clarified that the bills would not prohibit domestic research or ordinary medical practice with cleared vendors. Lawmakers said state action was appropriate where federal oversight or immediate federal law did not already prevent the risk.
Ending: Sponsors and advocates said they would continue to coordinate with federal authorities and with state agencies to refine the drafting and ensure clinical continuity while mitigating security risks.
